What Activist Investors Can Teach Biotech Companies

Episode Summary

Executive Summary: EY’s Jeff Green argues biopharma management should adopt an activist investor mindset to sharpen capital allocation, R&D funding, portfolio decisions, and governance. The discussion highlights a shift toward larger targets, stronger emphasis on operational efficiency and R&D productivity, and growing investor reward for focused businesses and strategic carve-outs.

Main Topics: Thinking Like Activist Investors (Priority: 5/5): Green explains that activists have gained influence by making compelling cases on cost, portfolio, and governance issues, and management teams can learn from their discipline. Capital Allocation and Cost Structure (Priority: 5/5): The conversation emphasizes reviewing whether a company’s cost base fits its strategy, and whether reductions could be executed faster in large biopharma companies. R&D Efficiency and Funding Discipline (Priority: 5/5): A major theme is how companies allocate R&D dollars, how objective those decisions are, and the difficulty of benchmarking true R&D productivity across firms and therapeutic areas. Portfolio Focus and Carve-Outs (Priority: 4/5): Green says activists increasingly argue that diversified companies may be worth more if separated, and investors have rewarded companies that sharpen their portfolios. Benchmarking, Disclosure, and Metrics (Priority: 4/5): The report urges better use of externally valid metrics like ROIC and TSR, while acknowledging that R&D decisions blend judgment with quantitative tools and remain opaque to outsiders. Outsourcing and External Innovation (Priority: 3/5): The discussion notes greater outsourcing of early-stage R&D as a useful complement to internal discovery, helping companies compare projects against external benchmarks. Deal Pricing and Return Risk (Priority: 3/5): Asset prices have risen across the sector, and while this may reflect better science and more strategic buying, it also raises the risk of overpaying and impairing returns.

Key Arguments: Shareholder activists have generally had a good recent track record in life sciences, attracting capital and influencing both institutional holders and company boards. The opportunity for activism has narrowed as stock prices and R&D performance improved, but gaps remain at large companies with bloated cost structures or future trial misses. Activists are shifting from small-company governance fights toward larger targets focused on operations, R&D allocation, and business separations. Management should pressure-test whether its cost structure, R&D spend, portfolio composition, capital allocation metrics, and shareholder communications are truly value-maximizing. R&D efficiency is difficult to benchmark externally because it varies by therapeutic area and depends on both rigorous process and informed judgment. Excessive quantification of pipeline value can be misleading; decisions need a balance of qualitative scientific judgment and objective analysis. More outsourcing of discovery can improve internal discipline by creating external benchmarks, but rising competition for assets has pushed valuations higher. Focused portfolios and virtual carve-outs have generally been rewarded by investors, suggesting the market favors clearer strategic stories and more concentrated businesses.

Data Points: Conference reference: 17th Annual Outsourcing and Clinical Trials New England 2025 Conference - Sponsor promotion for Prevail Infoworks Event dates: October 15th and 16th, 2025 - Prevail Infoworks conference appearance in Boston Industry report: EY report on capital allocation strategies in life sciences - Basis for the interview with Jeff Green Shareholder influence trend: Growing over the last few years - Green describes increasing activist impact across industries including life sciences Portfolio concentration example: Novartis and GSK exchange of assets - Used as an example of companies reducing the number of businesses they operate in Biotech bubble reference: 1999-2009 time period - Compared with the current biotech IPO environment to suggest science and investor behavior are different now

Pivotal Quotes: "management should learn to think more like activist investors" — Daniel Levine summarizing EY's report: Opening framing of the segment "the tools and the metrics being used consistent across the organization? And are they being driven by externally valid metrics, things like return on invested capital, things like total shareholder return?" — Jeff Green: Discussing how management should evaluate capital allocation "investors have rewarded people who focus their portfolios more" — Jeff Green: Explaining the market response to carve-outs and strategic focus

Implications: Biopharma leaders may need more rigorous, outsider-style scrutiny of R&D, cost, and portfolio choices. Investors will likely keep pressuring large companies to focus, justify spending, and improve returns.